Related references
Note: Only part of the references are listed.PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders
Shusuke Tomoshige et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Samir H. Barghout
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2021)
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
Ryosuke Shirasaki et al.
CELL REPORTS (2021)
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Satomi Imaide et al.
NATURE CHEMICAL BIOLOGY (2021)
Targeted protein degraders crowd into the clinic
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
Mengzhu Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Bifunctional small molecules that mediate the degradation of extracellular proteins
David F. Caianiello et al.
NATURE CHEMICAL BIOLOGY (2021)
The PROTACtable genome
Melanie Schneider et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Shanique B. Alabi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Selective autophagy as the basis of autophagy-based degraders
Daiki Takahashi et al.
CELL CHEMICAL BIOLOGY (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
ATTEC: a potential new approach to target proteinopathies
Zhaoyang Li et al.
AUTOPHAGY (2020)
Targeting selective autophagy by AUTAC degraders
Daiki Takahashi et al.
AUTOPHAGY (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Milka Kostic et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Yonghan He et al.
NATURE COMMUNICATIONS (2020)
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
NATURE (2020)
Lysosome-targeting chimaeras for degradation of extracellular proteins
Steven M. Banik et al.
NATURE (2020)
Autophagy in Human Diseases
Noboru Mizushima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Katherine A. Donovan et al.
CELL (2020)
First targeted protein degrader hits the clinic
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2019)
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Jo Ishizawa et al.
CANCER CELL (2019)
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Xiaoyu Zhang et al.
NATURE CHEMICAL BIOLOGY (2019)
Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation
Cristina Mayor-Ruiz et al.
MOLECULAR CELL (2019)
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Daiki Takahashi et al.
MOLECULAR CELL (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Gerard L. Brien et al.
ELIFE (2018)
Share Paper
